{
    "nctId": "NCT03753776",
    "briefTitle": "Phase III Trial Evaluating Radium Bromatum Homeopathic Treatment Efficacy on Radiodermatitis Prevention and Treatment for Breast Cancer Women",
    "officialTitle": "Phase III Trial Evaluating Radium Bromatum Homeopathic Treatment Efficacy on Radiodermatitis Prevention and Treatment for Breast Cancer Women",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 232,
    "primaryOutcomeMeasure": "Percentage diminution of grade 2 or higher radiodermatitis in Radium bromatum group",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Major patient;\n* Indication of curative intent radiotherapy for breast cancer treated with conservative treatment. Accepted radiotherapy scheme: 50 Gy (main) + 16 Gy on the tumor bed (additional dose);\n* Patient affiliated or entitled to a social security scheme;\n* Patient who signed an informed consent form.\n\nExclusion Criteria:\n\n* Pregnant or lactating woman;\n* Legal incapacity or limited legal capacity. Medical or psychological conditions that do not allow the subject to understand the study and sign the consent\n* Patient followed by a liberal homeopath;\n* Patient with bilateral breast cancer;\n* Patient with in situ breast cancer;\n* Patient with known cognitive impairment;\n* Patient with known allergy and / or intolerance and / or malabsorption to fructose, glucose, galactose;\n* Patient with a known deficiency in sucrase / isomaltase / lactase.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}